Definition:
According to WHO Pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.
Status of Pharmacovigillance in Nepal
GoN nominated Department of Drug Administration (DDA) in October 2004 as the focal point (National Pharmacovigilance centre) to liaison with WHO collaborating centre for International Drug Monitoring, Sweden and started collecting adverse drug reactions. Nepal became a WHO programme member in July 2006.
At present, there are 12 regional pharmacovigilance centers in Nepal
- Tribhuvan University Teaching Hospital, Maharajgunj
- Civil Service Hospital, Minbhawan
- Manipal Teaching Hospital, Pokhara
- KIST Medical College, Imadol
- Nepal Medical College Teaching Hospital, Jorpati
- Patan Hospital, Lalitpur
- B.P Koirala Institute of Health Science (BPKIHS), Dharan
- Dhulikhel Hospital, Banepa
- Shree Birendra Hospital, Chhauni
- Norvic International Hospital, Thapathali
- Nepal Cancer Hospital and Research Center, Harisiddhi
- College of Medical Sciences - Teaching Hospital
These regional pharmacovigilance centers operate under DDA (DDA being the National centre for ADR monitoring). The regional centers reports ADRs to the National center (DDA) via ‘Vigiflow’ (an online program) which are then forwarded to the Uppsala Monitoring Center (UMC) by the National Centre. The National database contains about 547 ADR reports so far.
No comments:
Post a Comment